DiaSorin stock trades at EUR 75.39 with volume 20.9 percent below average

Published on 10/08/2026 at 17:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin stock costs EUR 75.39 on October 8, 2026 after EUR 76.71. Volume on Euronext Milan was 165,030 versus 208,537 average.

Key points in brief

DiaSorin stock was at EUR 75.39 at Lang & Schwarz on October 8, 2026, minus 1.72 percent versus EUR 76.71.
Trading volume was 165,030 shares against an average of 208,537, a 20.86 percent shortfall.
The stock was 5.43 percent below its EUR 79.72 52-week high, with market capitalization at EUR 3.7 billion.
Fiscal 2025 revenue was EUR 1.195 billion and adjusted EBITDA was EUR 394 million.
DiaSorin has scheduled approval of its third-quarter 2026 results for November 12, 2026.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

At Lang & Schwarz, DiaSorin stock (ISIN IT0003492391) was at EUR 75.39 on October 8, 2026 at 5:52 p.m. CEST, minus 1.72 percent versus the prior close of EUR 76.71. The after-hours quote puts the medical diagnostics company below its recent market high.

After-hours price and volume

The bid was EUR 75.36 and the ask EUR 75.42 at Lang & Schwarz on October 8, 2026. On Euronext Milan, volume stood at 165,030 shares against an average of 208,537 shares on October 8, 2026, leaving turnover 20.86 percent below the average.

Stock stays below yearly high

DiaSorin was last at EUR 75.42 on Euronext Milan on October 8, 2026. Its 52-week range was EUR 52.34 to EUR 79.72, so the Lang & Schwarz price was 5.43 percent below the high and 44.03 percent above the low.

Market capitalization was EUR 3.7 billion on October 8, 2026. The price-to-earnings ratio was 23.49 and the trailing dividend yield was 2.00 percent, placing valuation metrics between the two comparison companies listed below.

Comparison with peers

DiaSorin (Euronext Milan, EUR): minus 1.72 percent, P/E 23.49, market capitalization EUR 3.7 billion

bioMérieux (Euronext Paris, EUR): minus 0.43 percent, P/E 20.62, market capitalization EUR 9.5 billion

Abbott Laboratories (NYSE, USD): minus 1.53 percent, P/E 31.28, market capitalization USD 168.2 billion

Fiscal 2025 sets the baseline

According to DiaSorin, fiscal 2025 revenue was EUR 1.195 billion, adjusted EBITDA was EUR 394 million and adjusted net profit was EUR 223 million. Free cash flow reached EUR 209 million in the same fiscal year, giving the market a dated operating reference alongside the current valuation.

Next results date is November 12

According to eMarketStorage in a filing dated October 5, 2026, DiaSorin scheduled board approval of its third-quarter 2026 results for November 12, 2026. The company described the date as indicative and said the investor conference call will take place on the same day.

Euro quote after the Xetra session

The Lang & Schwarz price of EUR 75.39 on October 8, 2026 at 5:52 p.m. CEST was minus 1.72 percent against the prior close of EUR 76.71. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.